GSK’s blockbuster respiratory jab has been approved for a younger age group in a boost for the drugmaker over rival Pfizer. The vaccine protects against respiratory syncytial virus (RSV) which causes cold-like symptoms but can be dangerous for the elderly, newborn babies and vulnerable people. Arexvy was the world’s first RSV jab when it launched in the US last year but it faces competition from alternatives made by Pfizer and Moderna. Yesterday’s announcement makes the £1.2billion vaccine the first RSV jab endorsed for the under-60s by the FDA. Arexvy brought in about £1.2billion in sales last year, beating the £699m in revenue that Pfizer’s rival drug generated.

Source: Daily Mail June 10, 2024 21:07 UTC